ArticlePloS one2026
Survival and disease burden of breast cancer (Monastir, Tunisia): A population-based cohort study (2002-2022).
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPopulation-based evidence on Breast Cancer (BC) survival and disease burden in Tunisia remains limited. This study aimed to describe BC survival and temporal trends, quantify the BC burden, and assess the impact of early diagnosis on survival and burden.
methodsWe conducted a descriptive population-based cohort study of women diagnosed with BC in Monastir between 2002 and 2014, with follow-up through January 2022. Overall survival was estimated using Kaplan-Meier methods, and factors associated with mortality were assessed using multivariable Cox regression. BC burden was quantified using disability-adjusted life years (DALYs), comprising years of life lost (YLLs) and years lived with disability (YLDs). Relative risks (RRs) and related measures were used to assess the association between stage at diagnosis and mortality.
resultsAmong 1,075 incident BC cases identified between 2002 and 2014, 21.4% were diagnosed at stage IV. By 2022, vital status information was available for 959 women. The crude and age-standardized mortality rates were 11.9 (95% CI, 8.5-15.4) and 12.5 (95% CI, 8.9-16.0) per 100,000 WY, respectively. Median survival was 187 months (95% CI, 163.7-210.2), reaching 226 months among women diagnosed at stages 0-I. Three-, five-, and ten-year survival rates were 77.0%, 70.0%, and 45.2%, respectively. Ten-year relative survival showed a significant upward trend among women aged 30-64 years, corresponding to the target population of the national BC early detection program (APC, 5.37%; 95% CI, 2.03-8.82; p = 0.005). The total BC burden was 10,665.4 DALYs, including 10,362 YLLs (97.3%). Median DALYs per patient was 28.0 years (IQR, 13.74-36.95). Diagnosis at stages 0-II was associated with a 22% reduction in ten-year mortality (RR, 0.78; 95% CI, 0.67-0.91), with an NND of 9. Diagnosing 61 women at stages 0-II rather than III-IV would avoid one DALY.
conclusionThe significant upward trend in ten-year survival among women targeted by the national BC early detection program, together with the avoidance of one DALY per 61 women diagnosed at stages 0-II rather than III-IV, supports continued investment in early detection and BC control in Tunisia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.